Mobascher A, Mobascher J, Schmahl C, Malevani J
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Heinrich-Heine-Universität , Bergische Landstrasse 2, 40629 , Düsseldorf.
Nervenarzt. 2007 Sep;78(9):1003-13. doi: 10.1007/s00115-006-2243-3.
Pharmacotherapy of Borderline personality disorder with atypical antipsychotics has recently been the subject of several mostly small studies and case reports. In contrast to the frequent clinical use of this substance class in borderline patients the amount of data on that subject is still sparse. The clinical data gathered thus far suggest a potential use of atypical antipsychotics in the areas of psychotic symptoms, impulsivity and possibly affective symptoms. The drugs were sufficiently well tolerated; however, the observation period in most studies was short and the dosage low. The current set of clinical data does not support the frequently applied polypharmacy. However, recent data suggest that a therapeutic approach combining atypical antipsychotics and psychotherapy may reveal synergistic effects. Future trials should study larger sample sizes over a longer period of time. Open questions are the required dose and the optimal treatment duration.
非典型抗精神病药物用于治疗边缘型人格障碍,最近已成为几项大多规模较小的研究及病例报告的主题。与该类药物在边缘型人格障碍患者中频繁的临床应用形成对比的是,关于这一主题的数据仍然稀少。迄今为止收集到的临床数据表明,非典型抗精神病药物在治疗精神病性症状、冲动行为以及可能的情感症状方面具有潜在用途。这些药物耐受性良好;然而,大多数研究的观察期较短且剂量较低。目前的临床数据并不支持频繁应用的联合用药方式。不过,最近的数据表明,将非典型抗精神病药物与心理治疗相结合的治疗方法可能会产生协同效应。未来的试验应研究更大样本量且更长时间的情况。尚待解决的问题是所需剂量和最佳治疗持续时间。